We only included data from published randomized clinical trials (either in a complete or abstract form) with HR+/HER2- BC patients who progressed on treatment with abemaciclib, palbociclib, or ribociclib plus ET in the metastatic setting or within 12 months of CDK4/6i exposure in the adjuvant setting. The gene discussed is HR; the disease is breast cancer.